Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2013—Abbott has received FDA approval to expand the use of its RealTime HIV-1 assay to run on the company’s mPlus system. In April, Abbott introduced mPlus capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient for laboratories.
AACC 2013 Abbott announced results from a study evaluating its high sensitive troponin-I (hsTnI) assay. The study, conducted by researchers at Brigham and Women’s Hospital, demonstrated that Abbott’s Architect stat hsTnI test may help doctors predict which patients presenting with symptoms of a heart attack are at a higher risk for having a heart attack 30 days after presentation. Researchers at Brigham and Women’s evaluated the performance of Abbott’s Architect stat hsTnI assay with the performance of a fourth-generation troponin
Eppendorf North America offers a new generation of its ThermoMixer and ThermoStat incubators. The excellent mixing results of the ThermoMixer C, F1.5 and FP (two-in-one instruments for combined mixing and incubating) are due to the company’s two-dimensional mix-control technology, which ensures fast and efficient mixing in seconds. Through controlled circular movements, liquids in small volumes are thoroughly mixed, while anti-spill technology prevents lid wetting and cross-contamination. For dry incubation, the company’s ThermoMixer C and ThermoStat C operate together with SmartBlocks,
Seegene has launched its multiple mutation detection technology to accelerate the development of companion diagnostic tests. The technology transforms conventional real-time instruments into powerful systems to simultaneously detect multiple mutation targets in a single channel. Seegene has extended the capabilities of its real-time PCR technology to simultaneously detect more than 20 different mutations, including insertions, deletions, and point mutations, in a single tube and single reaction. The technology detects minority mutation or species when wild-type is in excess of 10,000-fold
Greiner Bio-One’s Vacuette Tube-Touch passive safety device has a passive safety shield that activates upon tube insertion, reducing the risk of exposure to bloodborne pathogens from a needlestick. The product comes to the customer completely assembled with a needle, safety shield, and tube holder. Greiner Bio-One, 888-286-3883
Streck’s A1c-Cellular Linearity, an HbA1c linearity/calibration verification material with intact red blood cells, is now assayed for Roche Diagnostics’ Cobas c 311. It is a five-level assayed linearity material used to assess instrument accuracy and verify the patient reportable range of the HbA1c parameter. The product does not require reconstitution, which reduces the potential for human errors and saves time. The linearity material tests the entire reportable range of the instrument system, including the lyse step. Instrument-specific target values and
Radiometer America offers its “Avoid Errors” application for the iPhone. The app allows users to identify typical preanalytical errors in blood gas testing. The content of the “Avoid Errors” application is threefold, with tips on how to prevent errors, a troubleshooting section, and a skill test. A handbook section in the app contains videos that show how to properly collect a blood gas sample by arterial puncture, through an arterial line, or by capillary sampling. The handbook also describes several
Wako Diagnostics was issued three class III medical device licenses by Health Canada to market the uTAS-Wako i30 instrument with the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma.
Seegene announced that BioMérieux has licensed the company’s DPO and TOCE technologies for the development of multiplexed tests for food safety.
Magellan Diagnostics has received FDA 510(k) clearance to market its LeadCare Ultra benchtop blood lead testing system in the United States.
